Terra Innovatum and GSR III Acquisition Corp. File Form S-4 After Business Combination Announcement Advancing Public Listing

Transaction To Accelerate Terra Innovatum's Pathway to Commercialization of Groundbreaking Micro-Modular Nuclear Technology by 2028
NEW YORK, NY AND AUSTIN, TX / ACCESS Newswire / May 15, 2025 / Terra Innovatum Srl ("Terra Innovatum," or the "Company"), a developer of micro-modular nuclear reactors, and GSR III Acquisition Corp. ("GSRT") (Nasdaq:GSRT), a publicly traded special purpose acquisition company, today announced that Terra Innovatum and GSRT have filed a registration statement on Form S-4 with the U.S. Securities and Exchange Commission. This filing marks a key milestone toward the proposed business combination and public listing, intended to accelerate the deployment of Terra Innovatum's breakthrough micro-modular reactor technology, SOLO™, and expand access to clean, scalable and reliable energy.
In Picture (Left to Right): Anantha Ramamurti, Marco Cherubini, Massimo Morichi, Gus Garcia, Cesare Frepoli, Guillaume Moyen, Giordano Morichi, Alessandro Petruzzi, Lew Silberman, Luca Longobardi, Nicholas Hresko-Staab.
The business combination aims to enable Terra Innovatum to execute its mission to deliver low-carbon, cost-efficient, and reliable power. SOLO™ is the first micro-modular reactor designed to operate on widely available Low-Enriched Uranium (LEU) and is built using commercial off-the-shelf components. This approach significantly streamlines regulatory review and reduces both technical and supply chain risks. Earlier this year, Terra Innovatum submitted its regulatory engagement plan to the Nuclear Regulatory Commission (NRC), a critical step toward its targeted commercial deployment in 2028.
PUBLIC LISTING & TRANSACTION OVERVIEW
The proposed business combination is expected to generate up to approximately $230 million in gross proceeds before accounting for redemptions and any committed financing. This transaction values Terra Innovatum at a pre-money equity value of $475 million.
Following the completion of the transaction, the combined company will be led by Terra Innovatum's current management team under the name Terra Innovatum and is expected to trade on the Nasdaq under the ticker symbol "NKLR." Terra Innovatum shareholders will roll 100% of their equity into the newly formed public entity. The transaction has been unanimously approved by the Boards of Directors of GSRT and Terra Innovatum. Closing is anticipated to occur in the second half of 2025, subject to customary closing conditions.
Further details on the proposed transaction, including a copy of the business combination agreement and investor presentation, are contained in filings with the U.S. Securities and Exchange Commission (SEC), and are available at www.sec.gov.
ABOUT TERRA INNOVATUM & SOLOTM
Terra Innovatum is a pioneering force in the energy sector, dedicated to delivering innovative and sustainable power solutions. Terra Innovatum plans to leverage cutting-edge nuclear technology through the SOLO™ Micro-Modular Reactor (SMR™) to provide efficient, safe, and environmentally conscious energy. With a mission to address global energy shortages, Terra Innovatum combines extensive expertise in nuclear industry design, manufacturing, and installation licensing to offer disruptive energy solutions. Committed to propelling technological advancements, Terra Innovatum and SOLO™ are dedicated to fostering prosperity and sustainability for humankind.
It is anticipated that SOLO™ will be available globally within the next three years. Conceptualized in 2018 and engineered over six years by experts in nuclear safety, licensing, innovation, and R&D, SOLO™ addresses pressing global energy demands with a market-ready solution. Built from readily available commercial off-the-shelf components, the proven licensing path for SOLO™ enables rapid deployment and minimizes supply chain risks, ensuring final cost predictability. Designed to adapt with evolving fuel options, SOLO™ supports both LEU+ and HALEU, offering a platform ready to transition to future fuel supplies.
SOLO™ will offer a wide range of versatile applications, providing CO2-free, behind-the-meter, and off-grid power solutions for data centers, mini-grids serving remote towns and villages, and large-scale industrial operations in hard-to-abate sectors like cement production, oil and gas, steel manufacturing, and mining. It also has the ability to supply heat for industrial applications and other specialized processes, including water treatment, desalination and co-generation. Thanks to its modular design, SOLO™ can easily scale to deliver up to 1GW or more of CO2-free power with a minimal footprint, making it an ideal solution for rapidly replacing fossil fuel-based thermal plants. Beyond electricity and heat generation, SOLO™ can also contribute to critical applications in the medical sector by producing radioisotopes essential for oncology research and cancer treatment.
To learn more, visit www.x-solo.com.
IMPORTANT INFORMATION FOR SHAREHOLDERS
This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or constitute a solicitation of any vote or approval.
In connection with the business combination, a to-be-formed Dutch company ("Pubco"), GSRT and Terra Innovatum (the "Registrant Parties") have filed with the SEC a registration statement on Form S-4 (the "Registration Statement"), which includes a preliminary prospectus of Pubco relating to the offer of securities to be issued in connection with the business combination, and a preliminary proxy statement of GSRT to be distributed to holders of GSRT's ordinary shares in connection with GSRT's solicitation of proxies for a vote by GSRT's shareholders with respect to the Business Combination and other matters described in the Registration Statement. The Registrant Parties also plan to file other documents with the SEC regarding the business combination. After the Registration Statement has been declared effective by the SEC, a definitive proxy statement/prospectus will be mailed to the shareholders of GSRT. INVESTORS OF GSRT AND TERRA INNOVATUM ARE URGED TO READ THE REGISTRATION STATEMENT, THE PROXY STATEMENT/PROSPECTUS CONTAINED THEREIN (INCLUDING ALL AMENDMENTS AND SUPPLEMENTS THERETO) AND ALL OTHER DOCUMENTS RELATING TO THE BUSINESS COMBINATION THAT WILL BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE BUSINESS COMBINATION.
Investors will be able to obtain free copies of the proxy statement/prospectus and other documents containing important information about the Registrant Parties once such documents are filed with the SEC, through the website maintained by the SEC at http://www.sec.gov. In addition, the documents filed by GSRT may be obtained free of charge by written request to GSRT at 5900 Balcones Drive, Suite 100, Austin TX 78731.
PARTICIPANTS IN THE SOLICITATION
Each of the Registrant Parties, and their respective directors and executive officers, may be considered participants in the solicitation of proxies with respect to the potential transaction described in this communication under the rules of the SEC. Information about the directors and executive officers of GSRT is set forth in GSRT's filings with the SEC. Information regarding other persons who may, under the rules of the SEC, be deemed participants in the solicitation of the shareholders in connection with the potential transaction and a description of their direct and indirect interests will be set forth in the Registration Statement (and will be included in the proxy statement/prospectus) and other relevant documents when they are filed with the SEC. These documents can be obtained free of charge from the sources indicated above.
FORWARD LOOKING STATEMENTS
The statements contained in this press release that are not purely historical are forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding our expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "would" and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.
The forward-looking statements contained in this press release are based on our current expectations and beliefs concerning future developments and their potential effects on GSRT and the other Registrant Parties. There can be no assurance that future developments affecting GSRT and the other Registrant Parties will be those that we have anticipated. These forward-looking statements speak only as of the date this press release is delivered and involve a number of risks, uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (1) the occurrence of any event, change or other circumstances that could give rise to the termination of the definitive agreements with respect to the Business Combination; (2) the outcome of any legal proceedings that may be instituted against GSRT, any of the Registrant Parties, the combined company or others following the announcement of the Business Combination and any definitive agreements with respect thereto; (3) the inability to complete the Business Combination due to the failure to obtain approval of the shareholders of GSRT or the SEC's declaration of the effectiveness of the Registration Statement (which will include the proxy statement/prospectus contained therein) to be filed by the Registrant Parties or to satisfy other conditions to closing; (4) changes to the proposed structure of the Business Combination that may be required or appropriate as a result of applicable laws or regulations or as a condition to obtaining regulatory approval of the Business Combination; (5) the ability of Pubco to meet stock exchange listing standards following the consummation of the Business Combination; (6) the risk that the Business Combination disrupts current plans and operations of Terra Innovatum as a result of the announcement and consummation of the Business Combination; (7) the ability to recognize the anticipated benefits of the Business Combination, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably, maintain relationships with customers and suppliers and retain its management and key employees; (8) costs related to the Business Combination, including the reorganization described in the business combination agreement; (9) changes in applicable laws or regulations; (10) the possibility that the Registrant Parties or the combined company may be adversely affected by other economic, business, and/or competitive factors; (11) the amount of redemption requests made by GSRT shareholders and (12) other risk factors described herein as well as the risk factors and uncertainties described in the Form S-4 and GSRT's other filings with the SEC, as well as any further risks and uncertainties to be contained in the proxy statement/prospectus filed after the date hereof. In addition, there may be additional risks that neither GSRT nor any of the other Registrant Parties presently know, or that GSRT or the other Registrant Parties currently believe are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. Nothing in this communication should be regarded as a representation by any person that the forward- looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made.
None of GSRT, the other Registrant Parties, or any of their respective affiliates, officers, employees or agents, makes any representation or warranty, either express or implied, in relation to the fairness, reasonableness, adequacy, accuracy, completeness or reliability of the information, statements or opinions, whichever their source, contained in this press release or any oral information provided in connection herewith, or any data it generates and accept no responsibility, obligation or liability (whether direct or indirect, in contract, tort or otherwise) in relation to any of such information. GSRT, the other Registrant Parties and their respective affiliates, officers, employees and agents further expressly disclaim any and all liability relating to or resulting from the use of this press release and any errors therein or omissions therefrom. Further, the information contained herein is preliminary, is provided for discussion purposes only, is only a summary of key information, is not complete and is subject to change without notice.
In addition, the information contained in this press release is provided as of the date hereof and may change, and neither GSRT nor the other Registrant Parties undertakes any obligation to update or revise any forward- looking statements, whether as a result of new information, inaccuracies, future events or otherwise, except as may be required under applicable securities laws.
CONTACTS
Giordano MorichiPartner, Chief Business Development Officer & Investor RelationsTerra Innovatum SrlE: g.morichi@terrainnovatum.comW: www.x-solo.com
Anantha RamamurtiPresident, Chief Financial OfficerGSR III Acquisition CorpE: anantha@gsrspac.comP: (949) 468-7434
Nicholas Hresko-StaabMedia RelationsAlliance Advisors IRE: TerraIR@allianceadvisors.com
SOURCE: TERRA INNOVATUM SRL

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Forbes

10 minutes ago

• Forbes

Side Hustle Or Salary Bump? How Gen Z And Millennials Are Doubling Their Income In 2025

In 2025, Gen Z and millennials are approaching financial growth with bold new strategies. Faced with rising living costs, shifting job security, and a changing relationship with work, many young professionals aren't waiting around for promotions or cost-of-living adjustments. They're taking income into their own hands—either by asking for more at work or by building something outside of it. While some are successfully negotiating raises, others are diving into freelance gigs or microbusinesses. So which strategy actually works better, and which one is right for you? Let's look at the data behind each approach and what Gen Z and millennials should consider when deciding how to increase their income this year. Gen Z is entering the workforce with less patience and more pragmatism. They want purpose, but they also want pay. Nearly two-thirds of 18–35-year-olds in the U.S. already have or plan to start a side hustle, driven by rising costs and gig flexibility, according to a recent Side Hustle Nation report compiling U.S. demographic data. At the same time, younger workers are becoming more assertive about their worth in traditional employment. According to NASDAQ, 55% of Gen Z negotiated their starting salary – more than any other generation. Whether through entrepreneurship or self-advocacy, the trend is clear. Young professionals are getting louder about money. 1. The salary negotiation route Best for you if: You're established in your role, want to grow internally, and prefer a stable income stream. Negotiating your salary may not be glamorous, but it's one of the most powerful tools you have to increase earnings, especially in roles where your value is proven. According to a Pew Research summary, two-thirds of people who asked for a raise received a better offer. In fact, 38% were offered more than they requested. MorningStar reports that Gen Z graduates are aiming for starting salaries between $75,000 and $100,000. Career advisors say negotiation is one of the only ways to bridge that gap early. As Forbes contributor Benjamin Laker advises, aiming for a realistic target, like a 5–10% raise, is key to negotiation success, especially when aligning your request with business goals. Pros of negotiation: Raises can compound over time, increasing long-term earnings Builds confidence and self-advocacy skills Strengthens your brand within the company Challenges: May feel uncomfortable if you lack leverage or support Requires preparation, research, and timing Doesn't solve job dissatisfaction or stalled growth If you're performing well and haven't had a compensation review recently, it may be time to start the conversation. Whether it's a bold ask at work or a business built after hours, Gen Z is taking control of how they ... More earn. getty 2. The side hustle strategy Best for you if: You want flexibility, creative freedom, or feel limited in your current role. Side hustles have evolved beyond Etsy shops and rideshare gigs. Today, they include everything from digital consulting and online tutoring to resale businesses and niche content creation. According to Scripps News, 26% of Gen Z already hold a side job. Over half expect to manage multiple income streams within the next five years. The income can be significant. A LendingTree study found the average side hustle earns around $1,200 per month, although the median is closer to $400. More importantly, 61% of respondents said their side hustle income was essential to making ends meet. Forbes recently highlighted how pairing gig roles like tutoring and content creation has helped some earn up to $5,000 per month, demonstrating what's possible when combining high-demand gigs. Pros of side hustling: Offers creative control and financial autonomy Builds marketable skills you can carry into other roles Could grow into a full-time business Challenges: Requires time and discipline outside your 9 to 5 Income can be inconsistent or delayed Risk of burnout if poorly managed If you're already spending evenings helping friends with social media or running an online store, you may be further along than you think. 3. Choosing what works for you Instead of asking which strategy is better, consider which is more realistic and beneficial for your current situation. Questions to reflect on: Do I have leverage at work or standout results I can use in a raise conversation? Is my current role a long-term fit or a stepping stone? Do I have available time, even in short blocks, to dedicate to a side project? Am I more motivated by career progression or creative ownership? Answering these questions can help point you toward a path that plays to your strengths and fits your lifestyle. 4. Can you do both? In many cases, yes. But it takes strategy. Some professionals negotiate for better pay at work while launching a consulting gig on the side. Others use their side hustle to fund certifications that increase their earning power at their day job. Done carefully, this hybrid approach can create more financial flexibility and professional momentum. Just make sure to set boundaries. Time-box your side projects. Check for conflict-of-interest clauses. And be honest with yourself about what you can sustainably manage. Take control of your income story In a job market shaped by automation and changing values, Gen Z and millennials are no longer relying on annual reviews or climbing one rigid ladder. They're carving income paths of their own—sometimes inside the office, sometimes outside of it, and often both. You don't need to pick the 'right' path. You just need to pick the one that works for you. Whether that means having a bold conversation with your manager or turning your skills into something marketable after hours, the most important step is choosing to act.

Business Wire

22 minutes ago

• Business Wire

Domo and Burbio to Launch AI-Powered K-12 Education Data Intelligence Tool

SILICON SLOPES, Utah--(BUSINESS WIRE)--AI and data products company Domo (Nasdaq: DOMO) today announced its partnership with K-12 education data intelligence platform provider, Burbio. Burbio leverages Domo's award-winning embedded analytics solution, Domo Everywhere, to embed analytics and integrate Domo dashboards directly into its data intelligence platform, adding AI-powered tools that quickly deliver contextual insights for school district initiatives and discussions. "Working alongside Burbio offers insightful data products that help partner organizations find greater efficiencies in K-12 spending and operations.' - RJ Tracy, Chief Revenue Officer at Domo Burbio measures K-12 spending, policies, and operational data to provide insights for suppliers, policy makers, investors, researchers, and advocacy groups to better understand the K-12 market down to the school district level. Burbio entered the K-12 market in July 2020, launching the Burbio School Opening Tracker, which became the authority on K-12 learning modalities, measuring whether schools were open for in-person learning every day, only a few days a week (hybrid), or not at all (virtual) during COVID-19. With Domo Everywhere, Burbio creates a series of dashboards that serve as a single source of truth and curates actionable information from millions of pages of unstructured school district documents such as school board meeting minutes, strategic plans, state grants, staff turnover, district spending details, budgets, and more. Burbio's advanced AI enables customers to ask questions and receive contextual insights at scale — for virtually any question. 'Burbio has pioneered gathering and analyzing hard-to-find industry information and organizing for customers to act on,' said Burbio co-founder Julie Roche. 'Domo's intuitive, flexible, and dynamic service allows us to deliver the data in an easily digestible manner to customers so they can integrate into their sales and marketing workflows. Burbio works with customers across infrastructure, technology, STEM, security, tutoring, curriculum, staffing, and more, and the reception of our client base to the Domo platform has been terrific.' By using Domo's powerful embedded analytics capabilities through Domo Everywhere, Burbio enables education stakeholders to: Map and visualize district-level purchase intent signals across the country Identify districts considering specific initiatives like program expansions, curriculum changes, or infrastructure projects Analyze vendor market penetration and competitive dynamics Receive automated alerts on emerging opportunities from funding sources to district leadership changes to relevant mentions in district documents Monitor broader policy developments, including federal funding impacts "Working alongside Burbio offers insightful data products that help partner organizations find greater efficiencies in K-12 spending and operations,' said RJ Tracy, Chief Revenue Officer at Domo. 'Our work with Burbio is a great example of taking a historically challenging space for analytics, due to the fragmented and unstructured nature of data, and using the power of AI to create a powerful intelligence tool that delivers immediate, actionable insights.' To learn more about how innovative organizations like Burbio are partnering with Domo to build AI and data products that generate measurable business value, visit About Burbio Burbio is a K-12 business intelligence service that delivers critical insights for industry supplier and stakeholders. Datasets include school board meeting minutes, strategic plans, state grants, checkbook registers, ESSER III plans, district budgets, district staffing turnover tracking, and more. The information is delivered through a district profile that presents relevant information at the district level as well as through market-level reporting highlighting important trends. Burbio utilizes AI, keyword searching and categorization of spending activity to provide data in a format that can be easily integrated into client CRMs. About Domo Domo is an AI and Data Products platform that helps companies of all sizes leverage data and AI to drive value in today's data-driven world. Built around our customers' preferred data foundation, powered by our award-winning solution, and enriched with our partner ecosystem, the Domo platform enables users to prepare, visualize, automate, distribute, and build end-to-end data products that provide solutions across the entire data journey. From hydrating your data foundation, to building fully embedded applications that can be shared with your employees and customers, to deploying AI models across a variety of providers, Domo gives users the ability to build data products that generate measurable value for the business. For more information, visit You can also follow Domo on LinkedIn, X, and Facebook. Domo is a registered trademark of Domo, Inc.

Business Wire

23 minutes ago

• Business Wire

Galatea Bio and Fabric Genomics Partner to Deliver Comprehensive Genetic Testing for Common Diseases

MIAMI & OAKLAND, Calif.--(BUSINESS WIRE)-- Galatea Bio and Fabric Genomics, a GeneDx company, announced today a strategic collaboration to enhance genetic testing by incorporating both rare pathogenic variant analysis and polygenic risk scoring (PRS) to assess genetic susceptibility to common diseases. 'By leveraging Fabric Genomics' high-quality clinical gene panel interpretation to support Galatea's polygenic risk score reporting, we are enabling more personalized assessments of an individual's risk for common diseases,' said Martin Reese. The initial offering will include an inherited cardiovascular gene panel based on American Heart Association (AHA) recommendations, with additional PRS for cardiovascular related traits, including coronary arterial disease, high low-density lipoprotein (LDL), elevated triglycerides, low high-density lipoprotein (HDL), atrial fibrillation, hypertension, type 2 diabetes and hypothyroidism. A follow-up offering will integrate hereditary cancer panels with PRS for breast, colorectal, and prostate cancers. 'Galatea Bio is committed to making common genetic risk prediction more accurate for all,' said Carlos Bustamante, Ph.D., CEO & Co-Founder, Galatea Bio. 'Through our collaboration with Fabric Genomics, we're working to capture both rare and common genetic contributions to disease risk—delivering meaningful insights to individuals across the US and around the world.' This collaboration integrates Fabric Genomics' platform for clinical reporting and its expertise in clinical gene panel curation with Galatea Bio's advanced PRS algorithms. By combining these capabilities, the partnership provides both rare variant and polygenic genetic risk reporting using the Broad Clinical Lab's (BCL) Blended Genome - Exome. A key component of this collaboration is the integration of Galatea Bio's newly released individually-adjusted PRS solution, StrataRisk™ PRS, which provides genetic risk for individuals of all ancestries. This is made possible through a novel, proprietary algorithm that leverages data from the Galatea Bio Global Biobank to calibrate PRS scores against similar individuals in genomic ancestry space, ensuring equitable risk assessment across diverse populations. 'By leveraging Fabric Genomics' high-quality clinical gene panel interpretation to support Galatea's polygenic risk score reporting, we are enabling more personalized assessments of an individual's risk for common diseases,' said Martin Reese, Ph.D., President of Fabric Genomics. 'This combined approach allows us to better explain patients' results with a more accurate risk profile.' Evaluating both rare genetic disease variants and polygenic risk scores can have several advantages over reporting either of these independently. Traditional single-gene or multi-gene panel testing focuses on high-penetrance rare mutations, which capture a subset of patients with an inherited single gene disease and often results in negative or uncertain results, leaving many patients' risk unexplained. PRS, which aggregates the cumulative effect of numerous common genetic variants, can provide refined risk stratification. 'This collaboration between Fabric Genomics and Galatea Bio is enabled by our clinical Blended Genome - Exome,' said Niall Lennon, Ph.D., Chief Scientific Officer, Broad Clinical Labs. 'This is exactly the kind of application we envisioned for this cost-effective approach—one that will provide a more comprehensive view of genetic susceptibility to important common diseases.' About Fabric Genomics Fabric Genomics, a GeneDx company, is democratizing genomics-driven precision medicine. The company provides institutions with end-to-end clinical sequencing solutions that include the Fabric Enterprise software platform, assay design and validation support and the clinical interpretation services needed to scale genetic testing. At the core of this platform is a suite of sophisticated AI algorithms and data knowledge systems that turn data into expert clinical insights. Headquartered in Oakland, California, Fabric Genomics supports clinical applications across a variety of use cases including rare disease, oncology, cardiovascular, neurological and women's health. To learn more, visit and follow us on X and LinkedIn. About GeneDx At GeneDx (Nasdaq: WGS), we believe that everyone deserves personalized, targeted medical care—and that it all begins with a genetic diagnosis. Fueled by one of the world's largest, rare disease data sets, our industry-leading exome and genome tests translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery and improve health system efficiencies. For more information, please visit and connect with us on LinkedIn, Facebook and Instagram. About Galatea Bio Galatea Bio is an innovative, venture-backed biotechnology company that strives to advance 'Precision Health at Scale for All.' Founded by pioneers in the fields of population genetics and bioinformatics, Galatea Bio leverages cutting-edge ancestry algorithms to scale the promise of precision health to global populations, while maintaining a strong commitment to ethical research. The company is headquartered in Miami Lakes, Florida. For more information, visit or follow us on X and LinkedIn. About the Broad Clinical Labs Broad Clinical Laboratories was founded in 2013 as a non-profit subsidiary of Broad Institute of MIT and Harvard to accelerate the world toward a better understanding, diagnosis and treatment of disease by pursuing projects, developing products and driving adoption of cutting edge genomics technologies and novel molecular assays. Broad Clinical Labs is a leader in translational genomics, having sequenced over 700,000 genomes in service of its mission to accelerate the understanding and diagnosis of human disease. Forward Looking Statements This press release may contain 'forward-looking statements' within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements generally are identified by the words 'believe,' 'project,' 'expect,' 'anticipate,' 'estimate,' 'intend,' 'strategy,' 'future,' 'opportunity,' 'plan,' 'may,' 'should,' 'will,' 'would,' 'will be,' 'will continue,' 'will likely result,' and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) our ability to implement business combinations, plans, goals and forecasts, and identify and realize additional opportunities, (ii) the risk of downturns and a changing regulatory landscape in the highly competitive healthcare industry, (iii) the size and growth of the market in which we operate, (iv) our ability to pursue our new strategic direction, and (v) our ability to enhance our artificial intelligence tools that we use in our clinical interpretation platform. The foregoing list of factors is not exhaustive. A further list and description of risks, uncertainties and other matters can be found in the 'Risk Factors' section of our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and other documents filed by us from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and we assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. We do not give any assurance that we will achieve our expectations.